Özlem MERCAN, Zekiye ÜLGER, Cemile Handan MISIRLI, Recai TÜRKOĞLU

Optikospinal Multipl Skleroz Klinik Seyir ve İmmünolojik Parametreler

DOI: 10.26650/experimed.2018.18002Amaç: Optikospinal multipl sklerozun (OSMS) klinik seyrinin klasik multipl sklerozdan (MS) farklı olduğu bilinmekte, nöromyelitis optika (NMO) ile de benzerliği dikkat çekmektedir. Biz bu çalışmayla OSMS’i klasik MS ve NM’dan ayıracak immunolojik parametreler tanımlayıp hastalığın seyri ve tedavi seçimi açısından fikir vermesini amaçladık.Gereç ve Yöntem: Çalışmaya 20 MS, 14 OSMS, 18 NMO ve 21 sağlıklı kontrol olgusu alındı. Serum sitokin düzeyleri çoklu boncuk yöntemi ile ölçüldü. Sonuçlar ANOVA ve Tukey’in post hoc testi ile karşılaştırıldı.Bulgular: IL-8 düzeyleri MS ve OSMS gruplarında NMO ve sağlıklı kontrol grubuna göre anlamlı derecede düşük saptandı (p<0,0001). IL-6 düzeyleri ise NMO ve sağlıklı kontrol gruplarında MS ve OSMS grubundan anlamlı derecede düşüktü (p=0.042). Tümör nekrotizan faktör alfa (TNF-α) düzeyine bakıldığında NMO ve sağlıklı kontrol gruplarının MS ve OSMS gruplarından anlamlı derecede düşük olduğu görüldü (p<0,0001). Sonuç: Çalışmamız OSMS ve NMO hastalarında birbirinden farklı sitokin düzeylerinin olduğunu göstermiş ve özellikle spinal longitüdinal lezyonu olmayan, Aquaporin-4 (Aqp-4) negatif OSMS’nin bir NMO spektrum hastalığı varyantı olmadığını destekleyen bulgular sunmuştur.

Anahtar Kelimeler:

Optik sinir, spinal kord, demiyelinizan

Opticospinal Multiple Sclerosis Clinical Course and Immunological Parameters

DOI: 10.26650/experimed.2018.18002Objectives: The clinical course of opticospinal multiple sclerosis (OSMS) is different from that of classical multiple sclerosis (MS) and exhibits a remarkable similarity with that of neuromyelitis optica (NMO). This study aimed to define the immunological parameters of OSMS to distinguish OSMS from classic MS and NMO and to highlight the pathology of OSMS and treatment choice. Material and Method: In total, 20 patients with MS, 14 with OSMS, 18 with NMO, and 21 healthy controls were enrolled in the study. Serum cytokine levels were measured using the multiple bead method, and the results were compared with those obtained using the post hoc analysis of variance and Tukey’s test. Results: Interleukin (IL)-8 levels were significantly lower in the MS and OSMS groups than in the NMO and control groups (p<0.0001). IL-6 levels were found to be significantly lower in the NMO and control groups than in the MS and OSMS groups (p=0.042). Tumor necrosis factor alpha ( TNF-α) levels were significantly lower in the NMO and control groups than in the MS and OSMS groups (p<0.0001). Conclusion: The findings of our study suggest that people with OSMS and NMO exhibit different levels of cytokines and that Aqp-4-negative OSMS, which is not a spinal longitudinal disease, is not a variant of NMO.

Keywords:

Optic nerve, spinal cord, demyelinatic,

PDF

___

1. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127: 701-21.
2. Pan HF, Li XP, Zheng SG, Ye DQ. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 2013; 24: 51-7.
3. Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31: 711-21.
4. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
5. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283: R7-R28.
6. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-89.
7. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-27.
8. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125: 1450-61.
9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
10. Ramanathan S, Sato S, Matsushita T, Masaki K, Yamasaki R, Dale RC, et al. Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis. Mult Scler 2015; 22: 127-8.
11. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988-1002.
12. Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010; 120: 71-5.
13. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16: 1443-52.
14. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol 2001; 119: 297-305.
15. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2016; 138: 984-1010.
16. Lund BT1, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 2004; 155: 161-71.
17. Nozell S, Laver T, Patel K, Benveniste EN. Mechanism of IFN-β-mediated inhibition of IL-8 gene expression in astroglioma cells. J Immunol 2006; 177: 822-30.

Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 2011
Yayıncı: İstanbul Üniversitesi

Arşiv